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Abstract
Background: This paper describes the results of a feasibility study for a randomised controlled trial (RCT).
Methods: Twenty-nine members of the UK Dermatology Clinical Trials Network (UK DCTN) expressed an interest in
recruiting for this study. Of these, 17 obtained full ethics and Research & Development (R&D) approval, and 15 successfully
recruited patients into the study. A total of 70 participants with a diagnosis of cellulitis of the leg were enrolled over a 5-month
period. These participants were largely recruited from medical admissions wards, although some were identified from
dermatology, orthopaedic, geriatric and general surgery wards. Data were collected on patient demographics, clinical features
and willingness to take part in a future RCT.
Results: Despite being a relatively common condition, cellulitis patients were difficult to locate through our network of UK
DCTN clinicians. This was largely because patients were rarely seen by dermatologists, and admissions were not co-ordinated
centrally. In addition, the impact of the proposed exclusion criteria was high; only 26 (37%) of those enrolled in the study fulfilled
all of the inclusion criteria for the subsequent RCT, and were willing to be randomised to treatment.
Of the 70 participants identified during the study as having cellulitis of the leg (as confirmed by a dermatologist), only 59 (84%)
had all 3 of the defining features of: i) erythema, ii) oedema, and iii) warmth with acute pain/tenderness upon examination.
Twenty-two (32%) patients experienced a previous episode of cellulitis within the last 3 years. The median time to recurrence
(estimated as the time since the most recent previous attack) was 205 days (95% CI 102 to 308).
Service users were generally supportive of the trial, although several expressed concerns about taking antibiotics for lengthy
periods, and felt that multiple morbidity/old age would limit entry into a 3-year study.
Conclusion: This pilot study has been crucial in highlighting some key issues for the conduct of a future RCT. As a result of
these findings, changes have been made to i) the planned recruitment strategy, ii) the proposed inclusion criteria and ii) the
definition of cellulitis for use in the future trial.
Published: 26 January 2007
Trials 2007, 8:3 doi:10.1186/1745-6215-8-3
Received: 18 August 2006
Accepted: 26 January 2007
This article is available from: http://www.trialsjournal.com/content/8/1/3
© 2007 Thomas et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Trials 2007, 8:3 http://www.trialsjournal.com/content/8/1/3
Page 2 of 9
(page number not for citation purposes)
Background
Cellulitis of the lower leg is an acute, painful and poten-
tially serious infection of the skin and subcutaneous tis-
sue. It is very common and currently accounts for 2–3% of
hospital admissions [1]. The average length of inpatient
stay is 9 days (Hospital Episode Statistics, Department of
Health, 2002–2003), and 25–50% of treated patients suf-
fer further episodes and other morbidity, such as oedema
and ulceration when followed-up for a number of years
[1,2].
There are numerous risk factors for cellulitis of the lower
leg, including previous episodes of cellulitis; leg oedema
(especially lymphoedema); toeweb maceration (often
caused by tinea pedis); obesity and diabetes [2-4].
Approximately one third of patients have recurrent epi-
sodes, at least in part due to the above risk factors.
Existing evidence for the use of prophylactic antibiotics to
prevent further episodes is very limited. Two small RCTs
hint at possible benefit, but these studies are very small
(16 and 40 participants respectively) [5,6]. A large-scale,
multi-centre trial evaluating the use of prophylactic anti-
biotics for the prevention of cellulitis of the leg is planned
(PATCH study – Prophylactic Antibiotics for the Treat-
ment of Cellulitis at Home). Two parallel RCTs have now
been funded and are being co-ordinated through a net-
work of dermatologists, dermatology nurses and health
services researchers with an interest in research into skin
disease. However, prior to commencing and in order to
inform such a large trial, the feasibility study described
below was conducted. This study had the following objec-
tives: i) to inform the design of the RCT by gathering data
on demographics, baseline event rates and the impact of
eligibility criteria; ii) to test the feasibility of recruiting and
running such a trial through the UK DCTN; and iii) to col-
lect service users' views on the design and conduct of the
trial.
Methods
Design
This feasibility study had three aspects: i) structured inter-
views with patients admitted to hospital with a diagnosis
of cellulitis of the leg; ii) a questionnaire survey of recruit-
ing dermatologists; and iii) a focus group discussion
involving 5 patients with a history of recurrent cellulitis.
No specific interventions were administered during the
study.
Setting/participants
A total of 29 hospitals throughout the UK and Southern
Ireland volunteered to take part in the study. These com-
prised of 20 teaching hospitals and 9 district general hos-
pitals. Patients were asked to take part in the study if they
had been admitted to hospital with a diagnosis of celluli-
tis of the leg. All patients received standard treatment for
their cellulitis according to the treating physician's normal
practice.
Recruitment
Recruitment took place over a 5-month period from
November 2004 to March 2005.
All inpatients that had been identified as having cellulitis
of the leg were approached by a UK DCTN dermatologist
or dermatology nurse during their stay in hospital. Other
than a confirmed diagnosis of cellulitis of the leg, no addi-
tional inclusion/exclusion criteria were used in order to
test the effects of the proposed eligibility criteria for the
future RCT. Data were collected on patient demographics,
presenting clinical features and previous medical history.
At the end of the study period, a short postal survey was
completed by the recruiting physician/nurse. This was
used to highlight any methodological problems or con-
cerns encountered during the period of the study.
Involvement of service users
Part of the remit of the pilot study was to capture service
users' views on the trial design. Having been given a brief
description of the proposed study, participants were asked
to comment on their willingness (or otherwise) to take
part in a future RCT and to identify possible areas of con-
cern that may limit their involvement.
A focus group of five patients with experience of cellulitis
was convened in order to explore these issues more fully.
The discussion was audio-taped and fully transcribed for
analysis. Prior to discussing the implications of participat-
ing in the proposed RCT, members of the focus group
were given both written information and an oral presen-
tation, in which the key aspects of the trial were outlined.
Ethics/R&D
All necessary ethical and R&D approvals were in place
prior to commencement of the study. The study was
approved by the Metroplitan Multi-Centre Research Ethics
Committee (ref: 04/MRE11/26).
All data were entered onto a customised Microsoft® Access
database and analysed using SPSS, version 11.5.
Results
Recruiting centres
Of the 29 centres that had initially expressed an interest in
helping with recruitment for this trial, only 17 (59%) cen-
tres had all of the necessary approvals in place ready to
enrol patients at the start of the recruitment period (Figure
1). Of these, 15 centres actually recruited participants into
the study. The main limiting factors in obtaining theTrials 2007, 8:3 http://www.trialsjournal.com/content/8/1/3
Page 3 of 9
(page number not for citation purposes)
approvals were a lack of time and administrative resource
at the recruiting centres.
Participant recruitment
A summary of recruitment rates throughout the 5-month
recruitment period is presented in Figure 2. In 63% (42/
67) of the cases, participants were recruited from general
medical wards. Only 12% (8/67) came from dermatology
wards. The remainder came from a variety of sources
including orthopaedic, geriatric and general surgery
wards. A total of 70 participants were recruited from 15
centres. The median number of patients recruited was 3
per centre (min 0, max 12).
Impact of exclusion criteria
All patients with a diagnosis of cellulitis of the leg were
asked to take part in this study. However, for the purposes
of the RCT exclusion criteria will apply. Figure 2 presents
the likely implications of these exclusion criteria on the
overall recruitment rate. Of the 100 participants who were
Flow chart of recruiting centres Figure 1
Flow chart of recruiting centres. [* Two centres did not recruit any patient.]
29 centres initially
interested to take part in 
the PATCH Pilot Study 
Dropped out
n = 12 (41%) 
Approval process not complete  n = 5
Too busy    n  = 3
No response  n = 4
1 centre dropped-out
during the study
(investigator too busy)
Centres obtained ethics / 
R&D approvals
n = 17 (59%) 
Centres asked to obtain 
R&D approvals
Obtained MREC 
approvals and centres 
started recruiting patients 
16* centres finished
recruiting patients for the 
studyTrials 2007, 8:3 http://www.trialsjournal.com/content/8/1/3
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Impact of exclusion criteria on recruitment rates Figure 2
Impact of exclusion criteria on recruitment rates. [* Of the 26 participants who met the inclusion criteria and were willing to 
take part in the study, 9 had had a recurrence within the last 3 years (6 within the last 12 months).]
Excluded: (n = 30) 
Not clear if definite cellulitis n = 11 
Confused / very unwell n = 9 
Discharged   n  = 5
Declined   n  = 5
Asked to take part 
n = 100 (100%)
Recruited into pilot study
n = 70 (70%) 
Excluded (n=32):
Allergic to Pen V n=14
Preceding ulcer   n=13
Trauma / surgery n=2
Doctor not willing to randomise n=3
Willing to be randomised
n=38 (38%)
Yes
n=28
Not sure
n=5
No
n=5
Willing to take antibiotics
n=26 (26%)*Trials 2007, 8:3 http://www.trialsjournal.com/content/8/1/3
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initially identified, only 26 were potentially eligible and
willing to take part in the future RCT.
Participants' characteristics
A summary of participants' characteristics is presented in
Table 1. This confirms the importance of known risk fac-
tors for cellulitis, such as obesity, diabetes, lymphoedema
and toe-web maceration.
Definition of cellulitis
The criteria for defining an eligible case of cellulitis for
inclusion in the RCT were to be developed from the
results of this pilot study. As presented in Table 2, all of
the recruited patients were confirmed to have cellulitis of
the leg by a dermatologist or dermatology nurse. Entry cri-
teria based on the presence of i) erythema, ii) oedema,
and iii) warmth with acute pain/tenderness results in an
eligible population of 59 (84%). By including the addi-
tional criteria of constitutional disturbance (flu-like
symptoms), this rate falls to 39 (56%). Alternatively, the
use of unilateral disease as a defining feature (in combina-
tion with i to iii above) results in an eligible population of
55 (79%).
Previous episodes of cellulitis
Overall, 44% (30/68) of participants reported having had
a previous episode of cellulitis, although only 55% of
these (17/30) were admitted to hospital for the treatment
of their cellulitis during their most recent previous attack.
Seven percent of cases (2/29) received prophylactic antibi-
otics and 14% (4/29) were prescribed compression band-
ages. The number of previous episodes of cellulitis ranged
from 0 to 6 (median = 1). Based on those with a recur-
rence within the last 3 years (22/68, 32%), the median
time to recurrence was 205 days (95% CI 102 to 308).
(Figure 3). For those with a recurrence at any time (n =
30), the median time to recurrence was 293 (95% CI 169
to 417).
Treatment of the current episode
During the current episode of cellulitis, 45% (31/69) of
participants received IV treatment, 44% (30/69) received
a combination of IV and oral antibiotics; and 12% (8/69)
received oral antibiotics. Where data were available, the
duration of treatment was between 7 and 14 days.
Feedback of investigators
A summary of comments received by investigators is pre-
sented in Table 3. The main area of concern relates to the
identification of patients (only 42% of investigators felt
that this worked well). Similarly, there were concerns
about the time required to do the study and the lack of
administrative support; particularly in the preparation of
ethics applications and institutional approvals.
Feedback of participants
Feedback given during the structured interview high-
lighted particular areas of concern that might influence a
patient's decision to volunteer for a future RCT. These
included:
 not willing to take tablets/placebo
 not willing to take antibiotics (if not necessary for treat-
ment)
 worries about resistance to antibiotics
 inability to travel for the research
 too old for a long term study/long term commitment
 worried that could not drink alcohol during the trial
 previous bad reactions to antibiotics
 would prefer once a day rather than twice a day dosing
 concerns relating to co-morbidity.
Results of the focus group showed similar concerns. When
the participants were asked to discuss if, hypothetically,
they would be happy to take part in the study, it was evi-
dent that they required detailed information before being
able to make this decision, especially with regard to:
Table 1: Participant characteristics. [Note: with the exception of 
BMI, all variables had <3 missing values. For BMI data were 
missing for 24 cases due to difficulties in measuring the height 
and weight of patients.]
Characteristic n (%)
Male 41 (61)
Female 26 (39)
Age – mean 61 (s.d 16.0)
Age range 22 to 87
Body Mass Index – BMI (kg/m2)
Underweight (<20) 1 (2)
Normal (20 to 24.9) 11 (24)
Overweight (25 to 29.9) 8 (17)
Obese (>30) 26 (57)
Diabetes 14 (21)
Lymphoedema 11 (16)
Toe-web maceration 22 (32)
DVT prior to acute episode 2 (3)
Pre-existing ulcer 14 (20)
Previous blunt injury or scratch 19 (28)
Post operative or penetrative wound 6 (9)
Known allergy to penicillin 14 (20)
Previous episode (ever) 30 (44)
Previous episode in last 3 years 22 (32)Trials 2007, 8:3 http://www.trialsjournal.com/content/8/1/3
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 Concerns about taking antibiotics. This included issues
such as: drug interactions; GI side effects and building up
resistance; whether or not tablets should be taken on an
empty stomach and when they should be taken; and the
possibility of not being able to drink alcohol for the dura-
tion of the study.
 What would happen if they experienced another medi-
cal problem requiring hospitalisation and/or the use of
other antibiotics during the study?
 Keeping and using emergency antibiotics for acute
onset of an episode of cellulitis – would this be allowed?
 Were they allowed to take other medications during the
study?
 What would happen at the end of the study – could they
move onto other antibiotics or receive confirmed prophy-
laxis?
Interestingly, few issues were raised about taking placebo
(despite specific questioning). However, there was a reluc-
tance to stop taking current prophylactic antibiotics, as
those who were taking antibiotics in this way felt reas-
sured by their use.
Discussion
Main findings
This feasibility study proved invaluable in resolving sev-
eral crucial design issues for the future RCT. In particular
it addressed six key areas:
1) Identification of recruiting centres
Despite an enthusiastic response to the initial call for
recruiting centres, over 40% of those who expressed an
interest in the trial were unable to obtain the necessary
ethics and R&D approvals within the time window avail-
able. The increasing paperwork surrounding the conduct
of clinical trials following the introduction of the EU Clin-
ical Trials Directive, and the implementation of the
Research Governance Framework in the UK means that
much of this process is not optional. The set-up of this fea-
sibility study coincided with the introduction of the new
electronic form for ethics applications, and there were
inevitable teething problems associated with this develop-
ment. In addition, at the time of this research, many hos-
pital Trusts were not accepting the standard R&D
application form, thus making the R&D approval process
even more difficult. Considerable efforts have since been
made to streamline the approval process in the UK. Devel-
opments such as the on-line standard R&D form and the
plans to subsume site specific ethical review within the
local R&D approval process are to be welcomed.
2) Recruitment of participants
Recruitment for the pilot study was at approximately 1
patient per centre per month (15 per month in total).
However, the impact of applying exclusion criteria for the
RCT meant that this figure was dramatically reduced. Of
the 100 participants originally approached about the
study, only 26 (26%) fulfilled the eligibility criteria and
were willing to be randomised to treatment. In addition,
the impact of a more stringent definition of cellulitis
means that this figure could be reduced still further.
Time to recurrence for patients with a relapse within the last  3 years Figure 3
Time to recurrence for patients with a relapse within the last 
3 years.
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Table 2: Defining characteristics of cellulites
Characteristics n (%)
Cellulitis as confirmed by dermatologist/dermatology nurse 70 (100)
i) Erythema 69 (99) i, ii, & iii, 59 (84%)
ii) Oedema 63 (90)
iii) Warmth with acute pain/tenderness 66 (94)
iv)Constitutional disturbance 43 (62) iv plus i to iii above 39 (56%)
v) Unilateral disease 63 (90) v plus i to iii above 55 (79%)Trials 2007, 8:3 http://www.trialsjournal.com/content/8/1/3
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Investigators also reported that locating patients was diffi-
cult. This has worrying implications for an RCT involving
patients with cellulitis who are recruited by dermatolo-
gists in a secondary care setting. It is important to under-
stand why identifying patients with such a common
condition could be so difficult. Feedback from the recruit-
ing centres suggests that one of the most important limit-
ing factors for recruitment was that patients were not
routinely treated by dermatologists. Patients were seen by
many different disciplines (general medicine, infection
control, emergency medicine, geriatrics); were admitted
through various routes; and were often moved or dis-
charged at short notice. In addition, 6 centres established
a new system of community-based care during the period
of the pilot study. This meant that fewer patients were
treated for cellulitis in hospital and those that were admit-
ted were more likely to have multiple co-morbidities, or
to have cognitive impairment, making them unsuitable
for inclusion in a trial. It is likely that other hospitals will
adopt similar policies in the future.
The solution to different routes of admission for recruit-
ment seems to vary from hospital to hospital: providing
greater administrative support; posters on relevant wards;
identification of a link person (who may be a registrar or
research nurse, rather than necessarily the consultant);
tracking admissions from admission ward/casualty
department records; identification from clinical coding
records; and 'advertising' by a specific discussion of the
study at a postgraduate meeting or reminders at directo-
rate meetings are all possible methods to increase recruit-
ment.
3) Inclusion/exclusion criteria
Inclusion into the RCT will be based on a diagnosis of cel-
lulitis of the leg. However, cellulitis is a difficult diagnosis
to confirm by bacteriology and no guidelines exist relating
to clinical criteria for entry into trials. Obviously for any
future trials a balance must be struck between the specifi-
city and sensitivity of the chosen inclusion criteria. Simi-
larly, the impact of possible exclusion criteria was high. In
particular, 14 (20%) of those recruited into the pilot were
allergic to penicillin, and a further 13 (19%) had a preced-
ing ulcer, both of which are planned exclusion criteria for
the future RCT.
4) Primary outcome – time to recurrence
Data relating to time to recurrence suggest that the major-
ity of patients have a subsequent episode within a time
frame suitable for capture within the duration of a trial,
(indeed 75% occurred within 12 months of the previous
episode). In the 22 (32%) of participants who had experi-
enced a previous attack, the median time to recurrence
was 205 days (95% CI 102 to 308). This supports the need
for medium-term therapy for the 6 to 12 months period
immediately after an attack.
5) Views of service users
Most participants were supportive of the trial, particularly
if they had experienced several episodes of cellulitis in the
past. Nevertheless, many concerns were documented and
these will now be used when developing the participant
information sheets to be used in the future.
6) Views of investigators
Following this pilot study, the majority of investigators
were willing to recruit for the future RCT. However, many
were frustrated by the difficulties experienced in identify-
Table 3: Summary of lessons learnt from the feasibility study
Issue Problem Solution implemented for the RCT
Definition of cellulitis • Only 70% of those with cellulitis (as confirmed by a 
dermatologist) fulfilled the planned inclusion criteria to be used 
for the confirmation of cellulitis in the RCT.
• Inclusion criteria modified to be "Cellulitis as confirmed by a 
dermatologist". Individual clinical features will also be reported.
Recruitment • Considerable difficulties in relying on UKDCTN members to 
recruit into the study.
• Measures to increase recruitment include: displaying information in 
relevant clinics; presenting at hospital clinical meetings; recruiting 
through A&E and acute medical wards; identifying patients through 
coding departments; and paying for greater administrative support at 
the recruiting centres.
Definition of recurrent cellulitis • A definition of recurrent cellulitis for use in the trial was 
required.
• Recurrent cellulitis is defined as being "at least one previous 
episode of cellulitis of the leg within the preceding 3 years".
Alternative antibiotic for patients 
with penicillin allergy
• A surprisingly high proportion reported penicillin allergy (20%). 
Should an alternative be provided within the trial?
• No. The disadvantages (increased cost, more side effects and 
requirement for a double dummy) outweighed the recruitment 
advantage.
Treatment of existing risk factors • During the trial, dermatologists will be increasingly involved in 
the care of patients with cellulitis. If this alters the normal clinical 
practice of the treating physician, this could reduce the 
recurrence rates seen in the control arm. For example, should 
the dermatologists recommend treatment of tinea pedis?
• Unethical not to highlight the need for treatment if risk factors are 
observed. The treating physician will be asked to follow usual 
practice and risk factors treated on their merit.
Impact of antibiotic resistance • Concerns were expressed by patients, funding bodies and the 
ethics committee about the possible impact of long-term 
antibiotic therapy on microbial resistance.
• A review of the literature suggested that streptococcal infections 
have remained susceptible to penicillin for over 60 years, despite 
wide-spread use. There is no evidence to suggest that low-dose 
penicillin (which is currently used for other conditions, e.g.rheumatic 
fever) will lead to drug resistance. This fact is discussed at length in 
the supporting patient information leaflets.Trials 2007, 8:3 http://www.trialsjournal.com/content/8/1/3
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ing patients and with the level of paperwork required for
the ethics and R&D approval. Several felt that additional
resources, or the provision of administrative support
would make recruitment easier. One dermatologist
reported a tension between the need to identify potential
risk factors, such as toe-web maceration, and the desire to
provide treatment advice once this had been identified.
This has significant implications for the trial design as the
treatment of potential risk factors prior to discharge may
well impact on subsequent recurrence rates. If this is so,
the estimated power of the trial could be reduced.
Implications for the future trial
Many issues relating to the conduct and management of
the future RCT have been raised by this pilot study. Table
3 summarises the key discussion points raised, along with
the resulting conclusions. The overriding concern was to
design a pragmatic study, that reflected actual practice as
far as possible.
Two randomised controlled trials looking at the preven-
tion of cellulitis of the leg have since been funded (one by
Action Medical Research and one by the BUPA Founda-
tion – ISRCTN 34716921). These funding applications
were greatly enhanced by the preliminary work described
in this report and we were in a position to make informed
responses to the referees' comments as a result of it.
Conclusion
This preliminary work has proved invaluable in highlight-
ing some of the key issues to be addressed by an RCT of
prophylactic antibiotics for the prevention of recurrent
cellulitis. For a new clinical research network such as the
UK DCTN, this has also been an opportunity to establish
standard operating procedures and to train investigators
in the conduct of clinical trials.
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